Novel antiplatelet therapies

Current Atherosclerosis Reports

Volumn 14, Issue 1, 2012, Pages 78-84

  Kim, Luke ^a   Charitakis, Konstantinos ^a   Swaminathan, Rajesh V ^a   Feldman, Dmitriy N ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Antiplatelet; Aspirin; Cilostazol; GP IIb IIIa inhibitors; Thienopyridines; Thrombin receptor antagonists; Ticagrelor

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ATOPAXAR; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; ELINOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; METOPROLOL; OMEPRAZOLE; PLACEBO; PRASUGREL; PROTON PUMP INHIBITOR; THIENOPYRIDINE DERIVATIVE; THROMBIN RECEPTOR ANTAGONIST; TICAGRELOR; TICLOPIDINE; TIROFIBAN; VORAPAXAR;

ABCD1 GENE; ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADJUVANT THERAPY; ARTICLE; ATHEROSCLEROSIS; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLAUDICATION; CORONARY ARTERY DISEASE; CORONARY STENT; CYP 2C19C GENE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG METABOLISM; GENETIC POLYMORPHISM; HEART REINFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; LOSS OF FUNCTION MUTATION; LOW DRUG DOSE; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PERSONALIZED MEDICINE; PHARMACOGENETICS; PROGNOSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBOCYTE AGGREGATION INHIBITION; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS;

HEMORRHAGE; HUMANS; INCIDENCE; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RISK FACTORS;

EID: 84857789696     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-011-0216-x     Document Type: Article

References (59)

1. W Rosamond K Flegal G Friday, et al. 2007 Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 115 e69 e171 17194875 10.1161/CIRCULATIONAHA.106.179918 (Pubitemid 46226160)
2. Zipes DP, Libby P, Bonow RO, et al. Brauwalds heart disease: a textbook of cardiovascular medicine. 7th ed. Philadelphia: Saunders; 2005.
3. JL Anderson CD Adams EM Antman, et al. 2007 ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine Circulation 116 e148 e304 17679616 10.1161/CIRCULATIONAHA.107.181940
4. EM Antman DT Anbe PW Armstrong, et al. 2004 ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) Circulation 110 588 636 15289388 10.1161/01.CIR.0000134791.68010.FA (Pubitemid 39036178)
5. EPISTENT Investigators 1998 Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade Lancet 52 87 92 10.1016/S0140-6736(98)06113-3
6. ESPRIT Investigators 2000 Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial Lancet 356 2037 2044 10.1016/S0140-6736(00)03400-0 (Pubitemid 32009818)
7. HD Lewis JW Davis DG Archibald, et al. 1983 Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study N Engl J Med 309 396 403 6135989 10.1056/NEJM198308183090703 (Pubitemid 13033964)
8. JA Cairns M Gent J Singer, et al. 1985 Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial N Engl J Med 313 1369 1375 3903504 10.1056/NEJM198511283132201 1:STN:280:DyaL28%2FktVakuw%3D%3D (Pubitemid 16211835)
9. P Theroux H Ouimet J McCans, et al. 1988 Aspirin, heparin, or both to treat acute unstable angina N Engl J Med 319 1105 1111 3050522 10.1056/NEJM198810273191701 1:STN:280:DyaL1M%2FhsVKhug%3D%3D
10. The RISC Group 1990 Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease Lancet 336 827 830 10.1016/0140-6736(90)92336-G (Pubitemid 20311324)
11. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group 1988 Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2 Lancet 2 349 360
12. SR Mehta JF Tanguay JW Eikelboom, et al. 2010 (CURRENT-OASIS 7 trial investigators) double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial Lancet 376 1233 1243 20817281 10.1016/S0140-6736(10)61088-4 1:CAS:528: DC%2BC3cXht1KrsbbE
13. SR Steinhubl WA Tan JM Foody, et al. 1999 Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting JAMA 281 806 810 10071001 10.1001/jama.281.9.806 1:CAS:528: DyaK1MXhvVKrt78%3D (Pubitemid 29113740)
14. CAPRIE Steering Committee 1996 A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 348 1329 1339 10.1016/S0140-6736(96)09457-3 (Pubitemid 26383772)
15. S Yusuf F Zhao SR Mehta, et al. 2001 Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 494 502 11519503 10.1056/NEJMoa010746 1:CAS:528:DC%2BD3MXms1arsrY%3D (Pubitemid 32758501)
16. SR Steinhubl PB Berger JT Mann 3rd, et al. 2002 Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial JAMA 288 2411 2420 12435254 10.1001/jama.288.19.2411 1:CAS:528:DC%2BD38XoslOksL0%3D (Pubitemid 35340537)
17. MS Sabatine CP Cannon CM Gibson, et al. 2005 For the CLARITYTIMI 28 investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation N Engl J Med 352 1179 1189 15758000 10.1056/NEJMoa050522 1:CAS:528:DC%2BD2MXisFShsbY%3D (Pubitemid 40397259)
18. ZM Chen LX Jiang YP Chen, et al. 2005 COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial Lancet 366 1607 1621 16271642 10.1016/S0140-6736(05) 67660-X 1:STN:280:DC%2BD2MrptlKmtQ%3D%3D (Pubitemid 41552416)
19. G Patti G Colonna V Pasceri, et al. 2005 Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Circulation 111 2099 2106 15750189 10.1161/01.CIR.0000161383.06692.D4 1:CAS:528:DC%2BD2MXjtlKlsbk%3D (Pubitemid 40577905)
20. N Von Beckerath D Taubert G Pogatsa-Murray, et al. 2005 Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel. Results of the ISAR-CHOICE (Intracoronary stenting and antithrombotic regimen: choose between 3 high oral doses for immediate clopidogrel effect) Trial Circulation 112 2946 2950 (Pubitemid 41612296)
21. HJ Rupprecht P Widimsky R Afzal, et al. 2010 Dose comparisons of clopidogrel and aspirin in acute coronary syndromes N Engl J Med 363 930 942 20818903 10.1056/NEJMoa0909475
22. M Kazui Y Nishiya T Ishizuka, et al. 2010 Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite Drug Metabol Dispos 38 92 99 10.1124/dmd.109.029132 1:CAS:528:DC%2BD1MXhs1aqsr7L
23. M Gilard B Arnaud G Le Gal JF Abgrall J Boschat 2006 Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin J Thromb Haemost 4 2508 2509 16898956 10.1111/j.1538-7836.2006.02162.x 1:CAS:528:DC%2BD28Xht1yjtbfJ (Pubitemid 44575451)
24. M Gilard B Arnaud JC Cornily, et al. 2008 Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study J Am Coll Cardiol 51 256 260 18206732 10.1016/j.jacc.2007.06.064 1:CAS:528:DC%2BD1cXpt1Gksg%3D%3D
25. T Cuisset C Frere J Quilici, et al. 2009 Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose. The PACA (Proton Pump Inhibitors and clopidogrel Association) prospective randomized study J Am Coll Cardiol 54 1149 1153 19761935 10.1016/j.jacc.2009.05.050 1:CAS:528:DC%2BD1MXht1GntbbK
26. D Sibbing T Morath J Stegherr, et al. 2009 Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel Thromb Haemost 101 714 719 19350116 1:CAS:528:DC%2BD1MXltVertbs%3D
27. H Neubauer A Engelhardt JC Kruger, et al. 2010 Pantoprazole does not influence the antiplatelet effect of clopiodgrel: a whole blood aggregometry study after coronary stenting J Cardiovasc Pharmacol 56 91 97 20410834 10.1097/FJC.0b013e3181e19739 1:CAS:528:DC%2BC3cXovFSltL4%3D
28. JM Siller-Matula AO Spiel IM Lang G Kreiner G Christ B Jilma 2009 Effects of pantopraole and esomeprazole on platelet inhibition by clopidogrel Am Heart J 157 e1 e5 19081411 10.1016/j.ahj.2008.09.017
29. DL Bhatt BL Cryer CF Contant, et al. 2010 (COGENT Investigators). Clopidogrel with or without omeprazole in coronary artery disease N Engl J Med 363 1909 1917 20925534 10.1056/NEJMoa1007964 1:CAS:528:DC%2BC3cXhsVCht7rN
30. WC Lau PA Gurbel PB Watkins, et al. 2004 The contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance Circulation 109 166 171 14707025 10.1161/01.CIR.0000112378.09325.F9 1:CAS:528:DC%2BD2cXis1Citw%3D%3D (Pubitemid 38114134)
31. JS Hulot A Bura E Villard, et al. 2006 Cytochrome P450 2C19 loss-offunction polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2244 2247 16772608 10.1182/blood-2006-04-013052 1:CAS:528:DC%2BD28XhtVCgur7I (Pubitemid 44497506)
32. JL Mega SL Close SD Wiviott, et al. 2009 Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 354 362 19106084 10.1056/NEJMoa0809171 1:CAS:528:DC%2BD1MXhtVSlsbs%3D
33. AR Shuldiner JR O'Connell KP Bliden, et al. 2009 Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 849 857 19706858 10.1001/jama.2009.1232 1:CAS:528:DC%2BD1MXhtVCnt7zL
34. T Nguyen WH Frishman J Nawarskas, et al. 2006 Variability of response to clopidogrel: possible mechanisms and clinical implications Cardiol Rev 14 136 142 16628022 10.1097/01.crd.0000188033.11188.8e (Pubitemid 44350384)
35. T Simon C Verstuyft M Mary-Krause, et al. 2009 Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 363 375 19106083 10.1056/NEJMoa0808227 1:CAS:528:DC%2BD1MXhtVSlsbY%3D Variable response to clopidogrel plays an important role in determining the appropriate regimen for different individuals. Identification of genetic factors in clopidogrel metabolism may play a role in tailoring antiplatelet therapy to individual patients
36. ACCF/ACG/AHA 2010 Expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAIDS use. JACC. 2010;56:2052-2064.
37. PA Gurbel RC Becker KG Mann SR Steinhubl AD Michelson 2007 Platelet function monitoring in patients with coronary artery disease J Am Coll Cardiol 50 1822 1834 17980247 10.1016/j.jacc.2007.07.051 1:CAS:528:DC%2BD2sXht1Glur%2FE (Pubitemid 350007957)
38. L Bonello US Tantry R Marcucci, et al. 2010 Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate JACC 56 919 933 20828644 1:CAS:528:DC%2BC3cXhtlWjt7jJ
39. MJ Price PB Berger PS Teirstein, et al. 2011 (GRAVITAS Investigators). Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 1097 1105 21406646 10.1001/jama.2011.290 1:CAS:528:DC%2BC3MXjsFKgsb8%3D Despite the promise of tailoring clopidogrel therapy based on platelet inhibition, a large randomized trial failed to support this approach. Further studies will be necessary to identify better antiplatelet therapy for patients with high platelet reactivity
40. SD Wiviott D Trenk AL Frelinger, et al. 2007 Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial Circulation 116 2923 2932 18056526 10.1161/CIRCULATIONAHA. 107.740324 1:CAS:528:DC%2BD2sXhsVWjsr7N (Pubitemid 350291199)
41. SD Wiviott E Braunwald CH McCabe, et al. 2007 Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2001 2015 17982182 10.1056/NEJMoa0706482 1:CAS:528:DC%2BD2sXhtlWis7rN (Pubitemid 350106708)
42. The PRISM Study Investigators 1998 A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) N Engl J Med 338 1498 1505 10.1056/NEJM199805213382103 (Pubitemid 28226277)
43. The PURSUIT Trial Investigators 1998 Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy N Engl J Med 339 436 443 10.1056/NEJM199808133390704 (Pubitemid 28377685)
44. The EPIC Investigation 1994 Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty N Engl J Med 330 956 961 10.1056/NEJM199404073301402 (Pubitemid 24103593)
45. A Kastrati J Mehilli FJ Neumann, et al. 2006 Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment JAMA 295 1531 1538 16533938 10.1001/jama.295.13. joc60034 1:CAS:528:DC%2BD28Xjt12isbc%3D
46. RF Storey S Husted RA Harrington, et al. 2007 Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes J Am Coll Cardiol 50 1852 1856 17980251 10.1016/j.jacc.2007.07.058 1:CAS:528:DC%2BD2sXht1GlurzL (Pubitemid 350017792)
47. S Husted H Emanuelsson S Heptinstall PM Sandset M Wickens G Peters 2006 Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin Eur Heart J 27 1038 1047 16476694 10.1093/eurheartj/ehi754 1:CAS:528:DC%2BD28XlsFGqtLs%3D
48. L Wallentin RC Becker A Budaj, et al. 2009 Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes N Engl J Med 361 1045 1057 19717846 10.1056/NEJMoa0904327 1:CAS:528:DC%2BD1MXhtFaltL%2FJ Ticagrelor provides an alternative to clopidogrel with improved efficacy, without an increase in major bleeding events but with a higher rate of non-CABG-related bleeding
49. DL Bhatt AM Lincoff CM Gibson, et al. 2009 Intravenous platelet blockade with cangrelor during PCI N Engl J Med 361 2330 2341 19915222 10.1056/NEJMoa0908629 1:CAS:528:DC%2BD1MXhsFGltr7P
50. RA Harrington GW Stone S McNulty, et al. 2009 Platelet inhibition with cangrelor in patients undergoing PCI N Engl J Med 361 2318 2329 19915221 10.1056/NEJMoa0908628 1:CAS:528:DC%2BD1MXhsFGlsbfF
51. JS Berger MT Roe CM Gibson, et al. 2009 Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the early rapid Reversal of platelet thrombosis with intravenous elinogrel before PCI to optimize reperfusion in acute myocardial infarction (ERASE MI) pilot trial Am Heart J 158 998 1004 19958867 10.1016/j.ahj.2009.10.010 1:CAS:528: DC%2BD1MXhsFagsrzP
52. Rao S for the INNOVATE PCI investigators. A randomized, double-blind, active controlled trial to evaluate intravenous and oral PRT060128 (elinogrel), a selective and reversible P2Y12 receptor inhibitor vs clopidogrel as a novel antiplatelet therapy in patients undergoing nonurgent percutaneous coronary interventions. Stockholm: European Society of Cardiology 2010 Congress; 2010.
53. RC Becker DJ Moliterno LK Jennings, et al. 2009 Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study Lancet 373 919 928 19286091 10.1016/S0140-6736(09)60230-0 1:CAS:528: DC%2BD1MXjtFKqtrs%3D
54. DA Morrow BM Scirica KA Fox, et al. 2009 (TRA 2(o)P-TIMI 50 Investigators). Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial Am Heart J 158 335 341 19699854 10.1016/j.ahj.2009.06.027 1:CAS:528:DC%2BD1MXhtVegs7bL
55. ML O'Donoghue DL Bhatt SD Wiviott, et al. 2011 (LANCELOT-ACS Investigators). Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of thrombin-acute coronary syndromes trial Circulation 123 1843 1853 21502577 10.1161/CIRCULATIONAHA.110.000786
56. SD Wiviott MD Flather ML O'Donoghue, et al. 2011 (LANCELOT-CAD Investigators) randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of thrombin-coronary artery disease trial Circulation 123 1854 1863 21502571 10.1161/CIRCULATIONAHA.110.001404 1:CAS:528:DC%2BC3MXlsVynsbw%3D
57. SW Lee SW Park MK Hong, et al. 2005 Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis J Am Coll Cardiol 46 1833 1837 16286167 10.1016/j.jacc.2005.07.048 1:CAS:528:DC%2BD2MXht1SrtbzE (Pubitemid 41579804)
58. U Tamhane P Meier S Chetcuti, et al. 2009 Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials EuroIntervention 5 384 393 19736165 10.4244/V5I3A60
59. JW Suh SP Lee KW Park, et al. 2011 Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial J Am Coll Cardiol 57 280 289 21232664 10.1016/j.jacc.2010.08.631 1:CAS:528:DC%2BC3MXit1eqsrk%3D